On Thursday, March 11, the Maharashtra Food and Drugs Administration (FDA) said that it is working to bring down the cost of the Remdesivir 100 mg injection, used for treating critical COVID-19 patients.
As per the instructions of the state FDA minister Rajendra Shingane and Saurabh Vijay, Secretary, Department of Medical Education and Drugs, the administration has directed all producers of the injection that they must not print MRP more than 30 per cent margin after production and their rates of supply per injection.
It was observed that the manufacturers are supplying this injection at a cheaper cost of INR 800 to INR 1300 due to comparatively lesser demands than the initial days. But patients are not getting the benefit of the same cheaper prices. They are forced to purchase the injection at higher costs which are printed as MRP, the FDA said in the statement.
In this regard, meetings were held on March 6, 2021, and March 9, in the presence of Food and Drug Administration Commissioner Abhimanyu Kale. The administration has submitted a detailed report to the state government on this matter.
Moreover, the FDA has already sent a proposal to the Central government to fix the maximum retail price of 100 mg of the injection under the drug's price control, 2013.
Share
Tweet
